Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
359090
vs
K
KOSPI 200
Over the past 12 months, C&R Research Inc has outperformed KOSPI 200, delivering a return of +145% compared to KOSPI 200's +108% growth.
Stocks Performance
359090 vs KOSPI 200
Performance Gap
359090 vs KOSPI 200
Performance By Year
359090 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
C&R Research Inc
Glance View
C&R Research Inc. is a South Korean contract research organization that helps drug makers and medical device companies test products and win regulatory approval. It designs and runs clinical trials, manages study sites and patient data, and supports the paperwork needed to move a product from development into the market. Its customers are pharmaceutical companies, biotech firms, and device makers that need outside expertise to run complex trials correctly. The company makes money by charging fees for research and trial management services. In simple terms, it acts as a hired specialist between the company that invented a product and the regulators that must review it. That role matters because clinical research requires strict process control, local knowledge, and careful compliance, especially when trials span multiple sites or countries. What sets this business apart is that it does not sell a drug or device of its own; it sells the expertise, systems, and people needed to test someone else’s product. That gives C&R Research a service-based model tied to the pace of medical development and the demand for outsourced trial work. For investors, the key idea is that it sits in the middle of the healthcare development chain, earning revenue from project work rather than from product sales.